Autres langues Panbela Therapeutics, Inc.

Actions

SNBP

US69833W4042

Marché Fermé - OTC Markets Autres places de cotation 21:50:08 08/05/2024			Varia. 5j.	Varia. 1 janv.
0,382 ^USD	+0,26 %		-11,16 %	-97,91 %

22/04	Panbela Therapeutics, Inc. annonce que l'analyse des données intermédiaires de son essai ASPIRE en cours est repoussée au premier trimestre 2025	CI
18/04	Panbela annonce une présentation d'affiche à l'American Association for Cancer Research	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac	06/05
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024	01/05
Certain Stock Options of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Certain Warrants of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Certain Common Stock of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week	30/04
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025	22/04
Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025	22/04
Panbela Announces Poster Presentation at American Association for Cancer Research	18/04
Panbela Announces Poster Presentation at American Association for Cancer Research	18/04
Panbela Announces Poster Presentation At American Association for Cancer Research	18/04
Panbela Announces Transfer to OTCQB Market	16/04
Panbela Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results	26/03
Panbela Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024	12/03
Panbela Therapeutics, Inc.(OTCPK:PBLA) dropped from S&P TMI Index	11/03
Panbela Therapeutics, Inc.(OTCPK:PBLA) dropped from NASDAQ Composite Index	06/03
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements	15/02
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Panbela Therapeutics, Inc.

Actions

SNBP

US69833W4042

Autres langues

Filtres